1. Investing in Biotechnology Jessica Yu Biotech 2

2. Company Description (Week 0 – 7) Genentech, Inc. (DNA) -Goals: Discovering, developing, manufacturing, and commercializing biotherapeutics in the U.S. -Products: Avastin, Rituxan, Herceptin, Lucentis, Xolair, Tarvceva, Nutropin, Activase, TNKase, Cathflo Activase, Pulmozyme, Raptiva, -Number of shares purchased: 7 shares -Price per share at purchase: $78.30 Genzyme Corp. (GENZ) - Located in the U.S. the European Union, Latin America, and Asia Pacific - Consists of 5 specialized branches: Renal, Therapeutics, Transplant, Biosurgery, and Genetics - Products: Renagel, Hectoral vitamin D2 pre-hormone products, Cerezyme/Ceredase, Fabrazyme, Thyrogen, Myozyme, Aldurazyme, Thymoglobulin, Lymphoglobuline, Synvisc, Sepra products, - Number of shares purchased:7 shares - Price per share at purchase: $64.07

3. Company Description (Week 8 - 15) Questcor Pharmaceuticals, Inc. (QSC) -Goals: Novel therapeutics for treating diseases and diseases of the central nervous system -Products: H.P. Acthar Gel, Doral -Number of shares purchased: 500 shares -Price per share at purchase: $1.37 Sangamo Biosciences (SGMO) - Goals: Researching and developing novel DNA-binding proteins for therapeutic gene regulation and modification - Achievements: development of a class of DNA-binding proteins, called zinc finger DNA-binding proteints (ZFPs) - Number of shares purchased: 19 shares - Price per share at purchase: $18.86

4. Events Affecting Company Stocks Genentech, Inc. (-) - Alteration of a plan to discourage doctors from using Avastin to treat eye disease because of FDA concerns, but it also may have damaged Lucentis sales by angering retina specialists Genzyme Corporation (+) -the U.S. Food and Drug Administration has granted Epicel, its product for the treatment of life-threatening wounds resulting from severe burns Questcor Pharmaceuticals, Inc. (+) - U.S. shipments of its main product Acthar, a hormone used to treat swelling and allergic reactions, increased by 4 percent in December from the previous month Sangamo Biosciences (-) - Holder Kopp Investment Advisors cuts stake in Sangamo Biosciences to 7.2 percent

5. Performance Graphs

6. Stock Investment Summary -Total Stock Value at Purchase: $996.59 -Total Stock Value after 16 Weeks: $3057.39 -Net profit: $2060.80 -Percent Increase from Original Stock Value: +206.79%